Format

Send to:

Choose Destination
See comment in PubMed Commons below
Onco Targets Ther. 2010 Oct 11;3:205-10. doi: 10.2147/OTT.S13052.

Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics.

Author information

  • 1Pharmerit North America LLC, Bethesda, MD, USA.

Abstract

The use of indirect comparisons to evaluate the relative effectiveness between two or more treatments is widespread in the literature and continues to grow each year. Appropriate methodologies will be essential for integrating data from various published clinical trials into a systematic framework as part of the increasing emphasis on comparative effectiveness research. This article provides a case study example for clinicians using the baseline study population characteristics and response rates of the tyrosine kinase inhibitors in imatinibresistant or imatinib-intolerant chronic myelogenous leukemia followed by a discussion of indirect comparison methods that are being increasingly implemented to address challenges with these types of comparisons.

KEYWORDS:

BCR–ABL-positive chronic myelogenous leukemia; comparative effectiveness research; dasatinib; imatinib mesylate; meta-analysis; nilotinib

PMID:
21124747
[PubMed]
PMCID:
PMC2994202
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk